Erlotinib: A Targeted Anticancer Drug

Publisher： Bentham Science Publishers

E-ISSN： 1875-6301|13|1|3-16

ISSN： 1573-3947

Source： Current Cancer Therapy Reviews, Vol.13, Iss.1, 2017-08, pp. : 3-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background: Over expression of epidermal growth factor receptor (EGFR)has been found to play a vital role in cancer of lung and pancreas. Therapies that targetEGFR-mediated signalling are the latest keystone for treating these two types of cancer.lt;Pgt

Related content

Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells

By Lee Jaehyung   Gollahon Lauren  

International Journal of Oncology, Vol. 42, Iss. 3, 2013-03 ,pp. : 839-847 (9)

Spandidos Publications

Access to resources Recommend Favorite

Erlotinib

By Robinson Dean M.   Keating Gillian M.   Perry Caroline M.  

American Journal of Cancer, Vol. 4, Iss. 4, 2005-01 ,pp. : 247-252 (6)

Adis International

Access to resources Recommend Favorite

Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer

By Welch Stephen A   Moore Malcolm J  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 247-254 (8)

Future Medicine

Access to resources Recommend Favorite

Congrès Targeted Anticancer Therapies — TAT 2013

By Arrondeau J.   Helissey C.   Tlemsani C.   Boussion H.   Cohen R.   Riet F.   Vignot S.  

Oncologie, Vol. 15, Iss. 7-8, 2013-07 ,pp. : 415-423 (9)

Springer Publishing Company

Access to resources Recommend Favorite

Targeted delivery of anticancer agents using antibodies as vectors

By Toloudi Maria   Papasotiriou Ioannis  

memo - Magazine of European Medical Oncology, Vol. 6, Iss. 4, 2013-12 ,pp. : 262-266 (5)

Springer Publishing Company

Access to resources Recommend Favorite